Inaktiver Wert

Andere Sprachen Atossa Genetics Inc Nasdaq

Aktien

US04962H2094

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	15.05.
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial	15.05.
Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	15.05.
Atossa Therapeutics Files $100 Million Mixed-Shelf Offering	13.05.
Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	13.05.
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines	07.05.
Atossa Therapeutics, Inc. Announces Support of New Breast Cancer Screening Guidelines by U.S. Preventive Services Task Force	07.05.
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen	29.04.
Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen	29.04.
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer	16.04.
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	15.04.
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	15.04.
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference	11.04.
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09.04.
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	09.04.
North American Morning Briefing : Stocks Seen -2-	02.04.
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update	01.04.
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient	20.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Atossa Genetics Inc Nasdaq

Aktien

US04962H2094

Andere Sprachen

Filter